Page last updated: 2024-12-06
protizinic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
protizinic acid: RN given refers to cpd without isomeric designation; NM refers to (+-)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71862 |
| CHEMBL ID | 2105285 |
| CHEBI ID | 32067 |
| SCHEMBL ID | 25022 |
| MeSH ID | M0047778 |
Synonyms (42)
| Synonym |
|---|
| protizinic acid |
| prothizinic acid |
| 17190rp |
| 7-methoxy-alpha,10-dimethylphenothiazine-2-acetic acid |
| protizinic acid (jan/inn) |
| 13799-03-6 |
| D01185 |
| 2-(7-methoxy-10-methylphenothiazin-2-yl)propanoic acid |
| 54323-85-2 |
| 17190-rp |
| CHEMBL2105285 |
| acido protizinico |
| unii-n40195utpi |
| acidum protizinicum [inn-latin] |
| phenothiazine-2-acetic acid, 7-methoxy-alpha,10-dimethyl- |
| acido protizinico [inn-spanish] |
| einecs 237-453-0 |
| 10h-phenothiazine-2-acetic acid, 7-methoxy-alpha,10-dimethyl- |
| protizinic acid [inn:dcf:jan] |
| n40195utpi , |
| 2-(7-methoxy-10-methyl-2-phenothiazinyl)propionic acid |
| acide protizinique |
| acidum protizinicum |
| pirocrid |
| acide protizinique [inn-french] |
| AKOS015913792 |
| SCHEMBL25022 |
| 7-methoxy-.alpha.,10-dimethylphenothiazine-2-acetic acid |
| protizinic acid [mart.] |
| protizinic acid [mi] |
| protizinic acid [jan] |
| protizinic acid [who-dd] |
| protizinic acid [inn] |
| 10h-phenothiazine-2-acetic acid, 7-methoxy-.alpha.,10-dimethyl- |
| protizinsaure |
| CHEBI:32067 |
| FT-0699912 |
| DTXSID20864444 |
| Q27284520 |
| protizinicacid |
| CS-0026045 |
| HY-106555 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.68) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (30.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (10.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||